Articles tagged with Biopsies
A new AI model developed by St Andrews researchers can accurately classify endometrial biopsy whole slide images as malignant or benign, allowing pathologists to prioritize their workload and reduce diagnosis time. The final model achieved 97% accuracy in detecting malignant slides and 90% accuracy overall.
Researchers at Brigham and Boston Medical Center found associations between kidney damage and increased risk of heart disease and death. The study analyzed kidney tissue from 597 adults with chronic kidney disease, linking specific lesions to cardiovascular events.
Researchers at University of Birmingham develop AI diagnostic tool to predict ulcerative colitis flare-ups with 89% accuracy. The system identifies markers of inflammation and healing, providing analytical support for clinicians in managing the disease.
A study by researchers at TUM found that gut bacteria play a crucial role in liver regeneration. The microbiome produces short-chain fatty acids, which are essential for liver cell growth and division. In mice treated with antibiotics, liver regeneration was delayed or not possible, but a
A new AR system using HoloLens enables doctors to perform transperineal prostate interventions with high accuracy and flexibility. The system provides a 3D immersive experience, allowing doctors to guide needles to their target with ease.
Researchers developed a new device that detects and analyzes cancer cells in blood samples, enabling doctors to avoid invasive biopsies and monitor treatment progress. The Static Droplet Microfluidic device uses metabolic signatures to differentiate tumour cells from normal blood cells.
A new study found that individuals with a normal gastrointestinal biopsy still have a higher risk of developing inflammatory bowel disease (IBD) in the years following the biopsy. The study of over 450,000 individuals in Sweden showed that symptoms of IBD may start significantly before the disease shows up on biopsy.
Ultrafast MRI provides beneficial information for predicting DCIS upgrade to invasive cancer, including time to enhancement and lesion size. A study found that UF-MRI can accurately predict lesions diagnosed as DCIS at percutaneous biopsy that will be upgraded to invasive cancer at surgery.
Researchers at the University of East Anglia have developed a new blood test to detect prostate cancer with 94% accuracy. The Prostate Screening EpiSwitch (PSE) blood test significantly enhances overall detection accuracy for at-risk men, offering a rapid and minimally invasive diagnosis.
Researchers at Cedars-Sinai Cancer have developed a non-invasive test that can detect and profile prostate cancers in microscopic amounts. The test, known as the EV Digital Scoring Assay, has the potential to spare patients from unnecessary treatment-related side effects and direct them to effective therapies.
Researchers developed a novel CRISPR system to detect small amounts of cancer-related molecules in exosomes in plasma, effectively distinguishing between malignant and benign samples. The method has the potential to make cancer diagnosis and monitoring quicker and easier by analyzing blood samples.
Researchers developed a multimodal imaging-based tool, the active biopsy guidance system (ABGS), to improve oral cancer diagnosis. The ABGS provides clinically actionable direct visible guidance for biopsies, enhancing precision and potentially saving lives.
A new biopsy procedure is developed with a multispectral confocal endomicroscope to aid in lung tissue imaging. The system allows for simultaneous imaging of multiple fluorescent dyes, enabling unique identification and spectral unmixing.
A new study has identified distinct patterns of circular RNA expression in human ALS muscle tissue, which display disease-specific gradients and could inform about neuromuscular molecular programs in ALS. The research reveals that specific circRNAs are elevated in ALS muscle biopsies but reduced in spinal cord samples from ALS patients.
A new classification system, MPATH-Dx Version 2.0, has been developed to simplify diagnoses of melanocytic skin lesions. The system categorizes lesions into four classes, providing guidance on treatment and surveillance for patients.
A new AI algorithm, STORK-A, can predict IVF embryo viability with 70% accuracy, reducing the need for invasive genetic testing. The algorithm analyzes microscope images of embryos and incorporates information about maternal age and IVF clinic scoring to detect aneuploidy.
Researchers developed a laser-based approach to perform microbiopsies, enabling fast, painless tissue sampling with minimal damage. The novel technique uses laser ablation to extract tiny tissue volumes, which can be analyzed using virtual H&E imaging and other techniques in minutes, not hours.
Researchers found that P2-HNF4α expression is associated with p-STAT3 and c-Myc expression in NAFLD patients, suggesting potential biomarkers for hepatocellular carcinoma (HCC) risk. Additionally, p-STAT3 expression was linked to hypertension, while c-Myc expression was associated with advanced fibrosis.
NUS researchers have developed a low-cost, non-invasive cancer testing method that sequences clinical samples heated to isolate cancer-specific signatures in patient blood. The Heatrich-BS assay has high sensitivity comparable to gold standard CT scans and costs around US$35 from start to finish.
A new study suggests that blood tests can predict survival odds for patients with metastatic cancer by analyzing the proportion of tumor DNA in the bloodstream. Patients with higher levels of tumor DNA in their bloodstreams were found to have poorer survival rates across all cancer types studied.
A new study analyzed tumor biopsies from patients with newly-diagnosed germinal center B cell lymphoma and found that CREBBP mutations were associated with lower disease-free survival rates. The researchers identified CLMA as a practical tool to translate experimental findings into clinical applications.
A new study published in The Journal of Nuclear Medicine found that a PET/MRI machine learning model can reliably distinguish between patients with and without lymph node metastases. This breakthrough technology has the potential to eliminate sentinel lymph node biopsy, a common procedure for breast cancer treatment.
Researchers found that liquid biopsies can detect clonal haematopoiesis, a condition placing patients at higher risk of developing myelodysplastic syndrome or acute myeloid leukaemia. The study suggests that these patients should be referred for further evaluation to uncover actual risk and identify potential diagnostic pathways.
A USC-led team has found indications for an early breast cancer detection method using high-definition liquid biopsies. The test detected multiple cancer biomarkers, including 'oncosomes,' in the blood samples of most early-stage breast cancer patients.
Researchers at the University of Rochester have developed a novel 2-photon fluorescence microscopy imaging system that can detect basal cell carcinoma with perfect accuracy and squamous cell carcinoma with high accuracy. The system shortens the biopsy process to two minutes, enabling immediate treatment decisions for patients.
Researchers have developed a flexible endoscopic imaging probe using a bendable graded index (GRIN) lens, enabling 3D microscopic imaging of tissue. The new technology could shorten biopsy waiting times to minutes and enable real-time monitoring of tissue changes.
The Hastings Center introduces five ethical criteria to improve human subject protections in phase I healthy volunteer trials and research biopsies. These guidelines focus on translational science value, fair opportunity and burden sharing, fair compensation for service, experiential welfare, and enhanced voice and recourse.
Researchers from the University of Copenhagen have identified a new mechanism in ARVC that could lead to a potential treatment strategy. They found that activating sirtuin-3 can slow down disease progression, and honokiol, a natural product extracted from the tulip tree, has been shown to work similarly.
The contrast-enhanced in-phase Dixon sequence demonstrated higher sensitivity and reader confidence for detecting breast biopsy clips on MRI. The sequence also showed a higher contrast-to-noise ratio without affecting positive predictive value.
Researchers evaluated 35 commercial breast biopsy markers for ultrasound color Doppler twinkling, finding that three markers exhibited actionable twinkling for ≥2 transducers. Higher surface roughness was associated with actionable twinkling in C1-6 and 9L transducers.
A retrospective study found that patients with multiple architectural distortions on digital breast tomosynthesis were more likely to have high-risk pathology, but not significantly different frequencies of malignancy. Biopsy of all areas may be warranted for these patients.
A Nagoya University research group has developed an AI algorithm that can diagnose idiopathic pulmonary fibrosis with high accuracy, based on non-invasive examinations and medical data. The technology may revolutionize medical care by allowing doctors to request AI-assisted diagnoses instead of specialists.
Researchers at UC Santa Cruz discovered that a key genetic mutation in the KRAS gene alters RNA 'dark matter', leading to the release of previously unknown RNA biomarkers. These biomarkers could be detected in the blood through a liquid biopsy, offering a promising step in cancer early detection.
A rise in severe acute hepatitis of unknown causes (SAHUC) in children has been reported worldwide, with symptoms including jaundice, vomiting, and diarrhea. Diagnostic tests such as liver enzymes and biopsy reports can help identify the disease, but its etiology remains unclear.
Researchers found clots in small venous and arterial blood vessels in normal-looking skin from patients with severe COVID-19, distinguishable from other forms of respiratory illness. Antiviral proteins and interferon-induced inflammatory proteins were also detected, associated with disease severity.
A study of 45,000 women found significant racial and ethnic disparities in the time it takes to receive a biopsy after an abnormal screening mammogram result. Factors such as individual characteristics, neighborhood socioeconomic status, and healthcare access were also associated with delays in biopsies.
A study published in JAMA Oncology found significant disparities in breast biopsy delays among non-white women, with Black women experiencing the longest delays. Structural racism within healthcare facilities and screening site-specific factors contribute to these disparities.
Researchers at Tokyo Medical and Dental University have developed a liquid biopsy that can determine if an esophageal cancer patient will respond to certain treatments. The biopsy uses a panel of mRNAs and microRNAs to predict patient outcomes, with improved accuracy when combined with tumor size data.
Researchers discuss Hepatitis D's life cycle and interactions with its host, exploring strategies for further research to combat this overlooked virus. HDV coinfects people with hepatitis B, rapidly progressing to liver cirrhosis and cancer if left untreated, with a review published in the Chinese Medical Journal.
Researchers developed an AI model to analyze thyroid ultrasound images, identifying nodules unlikely to be cancerous with a sensitivity of 97%. This technology could reduce the number of unnecessary biopsies and assist radiologists in choosing which nodules should undergo biopsy.
Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
Patients with primary glomerular diseases have a significantly higher risk of cardiovascular events, including coronary artery disease and stroke. The study found that inclusion of kidney-specific risk factors improved the prediction of cardiovascular events.
A new virtual biopsy using cardiovascular magnetic resonance has been proven safe and effective in detecting signs of heart rejection in heart transplant patients. The non-invasive procedure reduces complications and hospital admissions compared to traditional invasive biopsies.
Researchers at Penn Medicine have developed an imaging agent that detects cancer cells in real-time during biopsies, offering promise for earlier and more accurate diagnoses. The technology, known as NIR-nCLE, uses a combination of near-infrared tracers and confocal laser endomicroscopy to identify microscopic cancer cells.
The Center of BioModular Multi-Scale Systems for Precision Medicine develops rapid next-generation tests for human ailments like cancer and COVID-19 using saliva, urine, or blood samples. The technology has already helped patients through commercial partnerships with private firms.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
Researchers have identified potential biomarkers in lupus nephritis through large-scale protein analysis, which may replace invasive tests. The study's findings could lead to more accurate diagnosis and treatment of the disease.
Researchers at Stevens Institute of Technology are developing a low-cost handheld device that can accurately diagnose skin cancers in just a few seconds. The device uses millimeter-wave imaging, which reflects differently on cancerous and healthy tissue, allowing for precise detection.
Researchers found that normal-appearing lupus skin contains the same inflammatory signals as skin with rashes, suggesting a primed state for inflammation. The study's findings provide new insights into how UV light triggers rashes in lupus patients and highlight the potential for precision medicine in treating the disease.
Recent studies found that pathologists perceive an overdiagnosis of melanoma, with many diagnosing cases as non-invasive melanoma despite variability in diagnoses. A study involving over 100 dermatopathologists showed a majority agree on the issue, but awareness may not be enough to reduce overdiagnosis.
Researchers at the Medical University of South Carolina have developed a highly accurate and minimally invasive test for detecting liver fibrosis. The test, GlycoFibroTyper, measures changes in sugar molecules attached to antibodies in patient blood samples.
Researchers developed a blood test to detect circulating melanoma cells, which can help diagnose skin cancer and monitor treatment response. The test uses the Melanoma-specific OncoBean platform conjugated with melanoma-specific antibodies.
A study suggests that accounting for genetic factors causing normal variations in PSA levels could improve the accuracy of prostate cancer detection. By analyzing data from over 95,000 men, researchers identified a polygenic score that accounted for 7.3-8.7% of variation in baseline PSA levels and was not associated with prostate cancer.
A study of 51,000 US veterans found a significant decrease in prostate cancer biopsies and diagnoses during the COVID-19 pandemic, with no racial disparity observed. The results suggest that the pandemic may have had a protective effect on prostate cancer diagnosis rates among Black and White veterans.
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
A new technology called MediSCAPE has been developed by Columbia Engineers that can capture real-time cellular detail in living tissues. This allows doctors to make informed decisions about tumor removal without needing to remove tissue and wait for pathology results.
A study published in JAMA Network Open found that half of all women will experience at least one false positive mammogram over a decade of annual breast cancer screening with 3D mammography. The risk of false positives is lower for women screened every other year, and non-dense breasts also show a lower false positive risk.
A pilot study suggests that an artificial intelligence system called CRANE can help cardiac experts diagnose rejection and estimate its severity more accurately. This could lead to faster diagnosis and treatment, as well as reduced variability in expert agreement, ultimately improving heart transplant outcomes.